Overview

Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver

Status:
Not yet recruiting

Trial end date:
2023-11-15

Target enrollment:

Participant gender:

Summary

This randomized clinical trial aims to compare the effect of the pioglitazone and SGLT2 inhibitor combination on liver fat mass, as compared to either drug used alone, with or without background medical therapy of metformin and/or DDP4 inhibitors.

Phase:

Phase 4

Details

Lead Sponsor:

Getz Pharma

Treatments:

Empagliflozin
Pioglitazone